Humanigen Inc (HGENQ)

[cowtown jay]

Dr. Daniel Thomas, one of the investigators in our CMML trial, will be moderating our presentation at the ASH Conference on Saturday, discussing the Complete Remission rates those cancer patients achieved with lenz.

"1852 Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia."

https://ash.confex.com/ash/2023/webprogram/Paper179706.html

This is in stark contrast to what Gilead achieved using magrolimab.

"Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS"

https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds

And of course, since our results were already published in the 'blood' journal, our presentation should be well-received.

https://ashpublications.org/blood/article/142/Supplement%201/1847/505640/Lenzilumab-in-Addition-to-Azacitidine-Improves

In addition, we know that this indication offered certain regulatory incentives. Will our demonstrated success result in an expedited approval or the award of a Priority Review Voucher? If so, will Humanigen announce that news this week, ahead of the conference, and perhaps with the announcement of the recall of our loaned shares?

Also, I see that another of our trial doctors, Dr. Saad Kenderian, who was also very excited about lenzilumab's performance in the LIVE-AIR trial, will also be moderating a separate presentation on Immunotherapies.

https://ash.confex.com/ash/2023/webprogram/Session24628.html

I hope shareholders can begin to see the long-awaited benefit of our faith In Humanigen, and in lenzilumab. It certainly looks promising.